CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in ...

Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis PASI Score Improvements Correlated with Downregulation ...

Idera Pharmaceuticals, Inc. announced top-line results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company's investigational oncology product candidate targeting Toll-like ...

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis "This Phase 2 trial of IMO-8400 will enable us to evaluate over a 12-week ...

CAMBRIDGE, Mass. and EXTON, Pa., May 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

Idera Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients with Psoriasis First Human Trial in Lupus Program Anticipated to Begin in 2012 CAMBRIDGE, Mass ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals (NAS: IDRA) today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements ...

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals (NAS: IDRA) ...